Study: NCT02060383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide s.c.
Description: Administered to Cushing's disease participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide s.c.
Description: Administered to Cushing's disease participants.

Intervention type: DRUG
Group type: OTHER
Intervention: Pasireotide s.c.
Description: Administered to Cushing's disease participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Participant switched to liraglutide if sitagliptin was found not to be effective.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin.

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Administered to Acromegaly participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Administered to Acromegaly participants.

Intervention type: DRUG
Group type: OTHER
Intervention: Pasireotide LAR
Description: Administered to Acromegaly participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin.